Jean-Pierre Sommadossi, Atea Pharmaceuticals CEO
Atea confirms unsolicited cash proposal from Tang Capital’s Concentra, the shell buying Jounce Therapeutics
Atea Pharmaceuticals, which went public in the fall of 2020 with the hopes of treating Covid-19 and other infectious diseases but has since struggled …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.